About this Research Topic
The influence of variable factors such as body composition and dietary choices on health systems and individuals is complicated. There are both beneficial and negative consequences of body composition and its lipid percentage. Lipids are an integral element of the cell membrane and supply precursors for growth and differentiation molecules. Food consumption and hepatocytes and other cells influence intracellular lipids content. Currently, a detailed transcriptomic and genomic analysis of fatty acid metabolism subtypes is still missing, and the consequences must be properly assessed. Under the umbrella of analytical research, its effects on several human health conditions, including Obesity, and Cancer, should be well addressed.
PDAC accounts for 95% of pancreatic tumors. Due to a lack of diagnostic biomarkers and early-stage symptoms, diagnosis often occurs at advanced and invasive stages. Current treatment options include surgery, chemotherapy, and radiation but all have poor efficacy and only modestly improve survival. In addition, overweight (BMI: 25–30 kg/m2) and obesity (30 kg/m2) are known cancer risk factors. They are accompanied with a range of metabolic and endocrine abnormalities involved in the pathophysiology of pancreatic cancer, including fatty acid metabolism disorder, insulin resistance, inflammatory processes, and disorders in hormonal changes and pancreatic steatosis. Many of these phenomena are also involved during pancreatic cancer progression, indicating that overweight and obese individuals should have an increased risk of cancer-related fatality. Thus, all of these ailments are interconnected in a complex manner.
Body Composition and lipid metabolism are not inherently good nor bad, but rather an unstoppable force that must be comprehended and redirected for the treatment of various pathologies. Based on the expression of multiple essential genes, a complete study and various experimental models may be used to generate a prognostic signature for pancreatic cancer. Therefore, this topic encourages novel research on the many facets of fatty acid metabolism and their effects on pancreatic cancer and other associated ailments.
Theme 1: Fatty acid metabolism in healthcare control;
Theme 2: Epidemiology: obesity and pancreatic cancer risk and outcomes;
Theme 3: Diet and body composition in obesity and pancreatic cancer risk;
Theme 4: Integration of metabolomics and transcriptomics of fatty acid metabolism
Theme 5: Single-cell transcriptome profiling for metabolic heterogeneity in human pancreatic cancers
Theme 6: Fatty acid metabolic reprogramming in pancreatic cancer: new therapeutic targets
Theme 7: Epigenetic modification of fatty acid synthase in pancreatic cancer
Preference is given to manuscripts that promote inter- and/or transdisciplinary research by applying innovative conceptual thought to theoretical models, existing methodologies, and strategy applications. In addition, innovations pertaining to the Sustainable Development Goals and potential impacts of fatty acid metabolism subtypes are of specific importance, so long as they highlight general or distinct efforts and identify current gaps in the health impacts of various diseases such as pancreatic cancer and obesity, as well as strategies for addressing them. We want substantial submissions based on original research, systematic reviews, or methodological developments.
PDAC accounts for 95% of pancreatic tumors. Due to a lack of diagnostic biomarkers and early-stage symptoms, diagnosis often occurs at advanced and invasive stages. Current treatment options include surgery, chemotherapy, and radiation but all have poor efficacy and only modestly improve survival. In addition, overweight (BMI: 25–30 kg/m2) and obesity (30 kg/m2) are known cancer risk factors. They are accompanied with a range of metabolic and endocrine abnormalities involved in the pathophysiology of pancreatic cancer, including fatty acid metabolism disorder, insulin resistance, inflammatory processes, and disorders in hormonal changes and pancreatic steatosis. Many of these phenomena are also involved during pancreatic cancer progression, indicating that overweight and obese individuals should have an increased risk of cancer-related fatality. Thus, all of these ailments are interconnected in a complex manner.
Body Composition and lipid metabolism are not inherently good nor bad, but rather an unstoppable force that must be comprehended and redirected for the treatment of various pathologies. Based on the expression of multiple essential genes, a complete study and various experimental models may be used to generate a prognostic signature for pancreatic cancer. Therefore, this topic encourages novel research on the many facets of fatty acid metabolism and their effects on pancreatic cancer and other associated ailments.
Theme 1: Fatty acid metabolism in healthcare control;
Theme 2: Epidemiology: obesity and pancreatic cancer risk and outcomes;
Theme 3: Diet and body composition in obesity and pancreatic cancer risk;
Theme 4: Integration of metabolomics and transcriptomics of fatty acid metabolism
Theme 5: Single-cell transcriptome profiling for metabolic heterogeneity in human pancreatic cancers
Theme 6: Fatty acid metabolic reprogramming in pancreatic cancer: new therapeutic targets
Theme 7: Epigenetic modification of fatty acid synthase in pancreatic cancer
Preference is given to manuscripts that promote inter- and/or transdisciplinary research by applying innovative conceptual thought to theoretical models, existing methodologies, and strategy applications. In addition, innovations pertaining to the Sustainable Development Goals and potential impacts of fatty acid metabolism subtypes are of specific importance, so long as they highlight general or distinct efforts and identify current gaps in the health impacts of various diseases such as pancreatic cancer and obesity, as well as strategies for addressing them. We want substantial submissions based on original research, systematic reviews, or methodological developments.
Keywords: PDAC, Metabolic subtypes, Lipid metabolism, biomarker, epigenetic metabolome, PDAC initiatives, Pancreatic steatosis, Clinical trials
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
